BidaskClub lowered shares of Chemed Corp. (NYSE:CHE) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, June 22nd.
Separately, Zacks Investment Research downgraded shares of Chemed Corp. from a buy rating to a hold rating in a research note on Tuesday, May 2nd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $186.00.
Shares of Chemed Corp. (CHE) opened at 202.00 on Thursday. Chemed Corp. has a 52 week low of $130.05 and a 52 week high of $216.01. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 29.64 and a beta of 1.15. The stock’s 50 day moving average is $205.67 and its 200-day moving average is $188.26.
Chemed Corp. (NYSE:CHE) last posted its quarterly earnings results on Wednesday, April 26th. The company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.04. The company had revenue of $405.90 million for the quarter, compared to the consensus estimate of $399.75 million. Chemed Corp. had a net margin of 7.14% and a return on equity of 24.62%. The firm’s revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 EPS. On average, equities analysts anticipate that Chemed Corp. will post $7.95 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/chemed-corp-che-cut-to-buy-at-bidaskclub-updated-updated-updated/1072904.html.
In related news, Director Donald E. Saunders sold 400 shares of Chemed Corp. stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $204.85, for a total value of $81,940.00. Following the sale, the director now owns 9,886 shares of the company’s stock, valued at approximately $2,025,147.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George J. Walsh III purchased 1,000 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The stock was bought at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the purchase, the director now directly owns 7,908 shares in the company, valued at approximately $1,617,660.48. The disclosure for this purchase can be found here. Insiders have sold a total of 5,400 shares of company stock valued at $1,104,850 over the last three months. 5.32% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in CHE. Glen Harbor Capital Management LLC boosted its stake in Chemed Corp. by 11.4% in the first quarter. Glen Harbor Capital Management LLC now owns 624 shares of the company’s stock worth $114,000 after buying an additional 64 shares in the last quarter. Tyers Asset Management LLC bought a new stake in Chemed Corp. during the fourth quarter worth about $124,000. TrimTabs Asset Management LLC boosted its stake in Chemed Corp. by 88.7% in the first quarter. TrimTabs Asset Management LLC now owns 732 shares of the company’s stock worth $134,000 after buying an additional 344 shares in the last quarter. Flinton Capital Management LLC bought a new stake in Chemed Corp. during the fourth quarter worth about $157,000. Finally, Whittier Trust Co. boosted its stake in Chemed Corp. by 4.6% in the first quarter. Whittier Trust Co. now owns 1,177 shares of the company’s stock worth $215,000 after buying an additional 52 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with our FREE daily email newsletter.